Remdesivir Criteria Save $500K-Plus Without Affecting Outcomes

By Ethan CoveyA systemwide shift to more restrictive remdesivir (Veklury, Gilead Sciences) eligibility criteria led to a substantial reduction in drug use and associated costs—without worsening clinical outcomes—according to a retrospective analysis.“This study was inspired by the rapidly changing dynamics of hospitalized COVID-19 care nationwide and the lack of evidence regarding the use of remdesivir in the later Omicron era,” said presenting author James Nicholson, Pha